Key facts
- Glafabra Therapeutics’s last known valuation is $65.0M.
- It has raised $200K.
- Notable investors include Innosphere Ventures, Rogue Funds.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Glafabra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Glafabra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glafabra Therapeutics
Provider of living cellular therapy services intended to treat enzyme deficiency disorders through a repeat-infusion model. The company uses engineered hematopoietic stem cells to restore missing enzymes, enabling patients with enzyme deficiencies to achieve durable therapeutic outcomes and reduced treatment frequency.
- Sector
- Healthcare
- HQ
- Park City, UT, United States
- Founded
- 2025
- Employees
- 12
- Website
- glafabra.com/
- Ownership
- Privately Held (backing)
Glafabra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glafabra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glafabra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.